Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on evobrutinib pharmacokinetics in healthy volunteers
NCT05248945Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evobrutinib, sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 19 and Maximum Observed Plasma Concentration at Day 19. Started Jan 2022; status: completed.
02
Drugs
evobrutinib
Beyond the preview
Go deeper on NCT05248945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248945.